CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Lopinavir/Ritonavir + hydoxychloroquineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1335 Levamisole Pill + Budesonide+Formoterol inhaler Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease

New Corona virus (COVID-19) has made a horrible situation for all of the countries. This disease is not only a health problem but also economy, culture and the whole entity of the countries is under attack by the virus. This disease seems to affect the body in two different pathology pathways. From one side virus can decrease activity of immune system in the blood stream and whole body and from other side it can attack the respiratory cells. Tissue biopsy shows that immune cells penetrate into the Lung tissue and we have accumulation and over activity of Immune cells in the lung. This inflammation in respiratory tract probably is the major cause of Cytokine storm and release of TNF-α and IL-6 into the blood. It seems that by three strategy disease can be treated. 1- By using systemic immune simulators. 2- By using topical anti-inflammatory drug in the respiratory system (Steroids or NSAIDs) 3- By inhibition of replication of the virus in the attacked cells.

NCT04331470 COVID-19 Drug: Levamisole Pill + Budesonide+Formoterol inhaler Drug: Lopinavir/Ritonavir + hydoxychloroquine

Primary Outcomes

Description: Chest Ct scan should be negative

Measure: Clear chest CT-scan

Time: between 3-7 days

Description: PCR test should be negative

Measure: PCR test

Time: between 3-7 days

Secondary Outcomes

Description: Patient should relief from signs of disease

Measure: Physical statues of patient

Time: Between 3-7 days


No related HPO nodes (Using clinical trials)